Goldman Sachs Upgrades Beam Inc (BEAM) to Conviction Buy
Get Alerts BEAM Hot Sheet
Price: $28.39 -2.34%
Rating Summary:
20 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
20 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Goldman Sachs upgraded Beam Inc (NYSE: BEAM) from Neutral to Buy and is adding the stock to its Conviction Buy List. The firm set a price target of $50, suggesting 19% upside.
The firm said BEAM offers above-average top-line growth potential and low-double-digit EPS growth over the next few years, citing: "(1) its attractive positioning within the growing bourbon category, (2) market share gains driven by stepped up investment and new innovation, (3) mid-teens EM sales growth, and (4) below-the-line leverage with a strong FCF profile driving $200 mn in buybacks over each of the next three years."
Goldman also said BEAM is an appearing potential M&A target, which provides support for the shares.
For more ratings news on Beam Inc click here and for the rating history of Beam Inc click here.
Shares of Beam Inc closed at $43.25 yesterday.
The firm said BEAM offers above-average top-line growth potential and low-double-digit EPS growth over the next few years, citing: "(1) its attractive positioning within the growing bourbon category, (2) market share gains driven by stepped up investment and new innovation, (3) mid-teens EM sales growth, and (4) below-the-line leverage with a strong FCF profile driving $200 mn in buybacks over each of the next three years."
Goldman also said BEAM is an appearing potential M&A target, which provides support for the shares.
For more ratings news on Beam Inc click here and for the rating history of Beam Inc click here.
Shares of Beam Inc closed at $43.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
- Bloom Burton & Co. Upgrades Aurinia Pharmaceuticals (AUPH) to Buy (1)
- William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Goldman Sachs Conviction Buy List, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share